American Pharmaceutical Partners Presents Abraxane Survival Data

American Pharmaceutical Partners has announced that the pivotal Phase III clinical study of Abraxane for injectable suspension in patients with metastatic breast cancer demonstrated a statistically significant improvement in survival in second-line patients.

The data were presented at the 22nd Annual Miami Breast Cancer Conference, and included for the first time an initial analysis of survival data from the prospectively randomized trial of 460 patients with metastatic breast cancer. The study population included patients who were previously untreated and those who were previously treated (second-line or greater-line therapy) for metastatic breast cancer.

In the overall patient population, median survival for those patients receiving Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) was 10 weeks longer than for patients receiving Taxol, but this difference did not reach statistical significance. However there was a significant prolongation in survival in patients receiving Abraxane in the second-line or greater setting as compared to those receiving Taxol. In this group, there was a 29 percent reduction in the risk of death for patients who received Abraxane compared to those who received Taxol.